Management of attention-deficit hyperactivity disorder

Convolutional neural network framework for EEG-based ADHD diagnosis in children

Purpose

Attention-deficit hyperactivity disorder (ADHD) stands as a significant psychiatric and neuro-developmental disorder with global prevalence. The prevalence of ADHD among school children in India is estimated to range from 5% to 8%. However, certain studies have reported higher prevalence rates, reaching as high as 11%. Utilizing electroencephalography (EEG) signals for the early detection and classification of ADHD in children is crucial.

Methods

In this study, we introduce a CNN architecture characterized by its simplicity, comprising solely two convolutional layers. Our approach involves pre-processing EEG signals through a band-pass filter and segmenting them into 5-s frames. Following this, the frames undergo normalization and canonical correlation analysis. Subsequently, the proposed CNN architecture is employed for training and testing purposes.

Results

Our methodology yields remarkable results, with 100% accuracy, sensitivity, and specificity when utilizing the complete 19-channel EEG signals for diagnosing ADHD in children. However, employing the entire set of EEG channels presents challenges related to the computational complexity. Therefore, we investigate the feasibility of using only frontal brain EEG channels for ADHD detection, which yields an accuracy of 99.08%.

Conclusions

The proposed method yields high accuracy and is easy to implement, hence, it has the potential for widespread practical deployment to diagnose ADHD.

Blood Levels of Trace Elements in Children with Attention-Deficit Hyperactivity Disorder: Results from a Case-Control Study

Some trace elements may participate in the pathogenesis of attention-deficit hyperactivity disorder (ADHD). This study aimed to investigate the trace element status of zinc (Zn), copper (Cu), iron (Fe), magnesium (Mg), and lead (Pb) in children with ADHD, and to compare them with normal controls. Associations between examined elements and SNAP-IV rating scores of ADHD symptoms were also assessed. Four hundred nineteen children with ADHD (8.8 ± 2.1 years) and 395 matched normal controls (8.9 ± 1.7 years) were recruited in the study. The concentrations of Zn, Fe, Cu, Mg, and Pb in the whole blood were measured by atomic absorption spectrometry. Lower zinc levels (P < 0.001) and the number out of normal ranges (P = 0.015) were found in children with ADHD when compared with the normal control group. The difference remained when adjusting the factor of BMI z-score. No significant between-group differences were found in levels of other elements. Zinc levels were negatively correlated with parent-rated scores of inattentive subscale of SNAP-IV (r = - 0.40) as well as with total score of SNAP-IV (r = - 0.24). Other significant associations were not observed. The present results indicated that there were alterations in blood levels of zinc, which was associated with the symptom scores of ADHD.

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial

BACKGROUND

In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.

OBJECTIVE

The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients with ADHD in Zahedan, Iran.

METHODS

In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.

RESULTS

Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven children (17.5%) were girls. Mean severity of signs in the group under methylphenidate plus PUFA treatment was 39.9±4.9 before treatment and 20.1±6.0 after 8 weeks of treatment (p<0.001). Mean severity of signs in the group under methylphenidate plus placebo treatment was 41.2±2.7 before treatment and 26.1±9.0 after 8 weeks of treatment (p<0.001). Mean reduction in the severity of symptoms in the group under methylphenidate therapy was 19.7±5.9 and in PUFA and placebo group it was 15.1±9.3 (p<0.067). Response to treatment (a reduction of at least 25% in the signs) in the group taking methylphenidate plus PUFA was 90% (18 patients) and in methylphenidate plus placebo group, it was 60% (12 patients) (p=0.028).

CONCLUSION

This study shows that PUFA is an efficient nutrient to treat ADHD and it can be used to treat patients. However, definitive conclusion requires repeating the study with a larger sample and longer study period.

TRIAL REGISTRATION

The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015092724209N2.

FUNDING

The authors received no financial support for the research, authorship, and/or publication of this article.